• About
  • Blog
  1. Home
  2. Blog
  3. Companies
  4. REGN

Regeneron Pharmaceuticals, Inc.(REGN)

NASDAQ Global Select
Sector: Healthcare | Industry: Biotechnology
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Latest News & Analysis

Group of business professionals in a modern office with abstract charts on digital screens, purple tones
Jul 28, 2025

Regeneron Pharmaceuticals Q2 2025 Analysis: Dupixent Growth and Strategic Diversification Insights

Explore Regeneron's Q2 2025 financials, Dupixent's growth, Eylea's competitive challenges, and strategic diversification into oncology and obesity markets.

Read more →
Professional businesswoman presenting in a modern office with soft abstract purple decor
Jul 28, 2025

Regeneron Pharmaceuticals (REGN) Navigates Eylea Decline with Dupixent Growth and Oncology Expansion

Regeneron (REGN) tackles Eylea sales decline through Dupixent expansion, Lynozyfic launch, and pipeline diversification. Insights on financial impact and strategy ahead of Q2 earnings.

Read more →
Abstract molecular structure in a modern laboratory with a soft purple background
Jul 11, 2025

Regeneron Pharmaceuticals: Lynozyfic Approval Drives Growth Amid Oncology and Obesity Pipeline Expansion

Regeneron's Lynozyfic FDA approval marks a strategic milestone, boosting oncology prospects alongside Dupixent sales and obesity pipeline advancements.

Read more →
Medical vials and pills on a laboratory bench with blurred purple-accented background
Jul 4, 2025

Regeneron Pharmaceuticals 2025 Update: Lynozyfic Approval, Oncology Expansion & Financial Analysis

Regeneron’s FDA approval of Lynozyfic marks a strategic pivot into oncology, diversifying revenue beyond Eylea amid strong financial fundamentals.

Read more →
Sleek medicine vial with measuring spoon on a clinical countertop and abstract purple molecular shapes in background
Jul 3, 2025

Regeneron Pharmaceuticals Strategic Growth and Financial Analysis Amid Obesity Market Expansion

Regeneron pivots with dual GLP-1/GIP obesity drug HS-20094, counters Eylea sales decline, and bolsters pipeline with Dupixent growth and 23andMe data acquisition.

Read more →
Group of researchers at a table with medical equipment and a softly blurred purple background
Jul 2, 2025

Regeneron Pharmaceuticals Growth Drivers and Strategic Market Positioning | Monexa AI

Explore Regeneron's latest growth catalysts, including Dupixent expansion, Lynozyfic launch, EYLEA challenges, and strategic financial performance insights.

Read more →
Group of scientists at a glass table in a modern office with a soft purple-themed background
Jun 27, 2025

Regeneron (REGN) Financials: Dupixent & Eylea Competitive Analysis

Deep dive into Regeneron's recent financial performance, Dupixent's surge, the strategic obesity pipeline, and Eylea's resilience amidst competition.

Read more →
Vials and pill bottles on a glass surface in front of a blurred lab background
Jun 25, 2025

Regeneron's Strategic Expansion: Dupixent & Obesity Pipeline Fuel Growth

Regeneron's latest FDA approval for Dupixent in bullous pemphigoid and its strategic entry into the obesity market with HS-20094 signal robust future growth.

Read more →
Scientist in lab coat analyzing test tubes in a modern laboratory with a purple-toned background
Jun 20, 2025

Regeneron's Dupixent FDA Approval for Bullous Pemphigoid: Analysis

Regeneron's Dupixent receives FDA approval for Bullous Pemphigoid, marking a significant expansion of its therapeutic reach and reinforcing the company's leadership in biologics.

Read more →
Two scientists analyze data in a high-tech lab with purple lighting and advanced biotech equipment
Jun 17, 2025

Regeneron (REGN): Strategic Moves & Dupixent's Clinical Triumph

Regeneron's strategic pivot: withdrawing 23andMe bid while Dupixent achieves clinical triumph, showcasing disciplined capital allocation and pipeline strength.

Read more →
Laboratory scene with scientists examining digital tablets amid advanced equipment and a soft purple backdrop
Jun 16, 2025

Regeneron's Strategic Evolution: Dupixent's Clinical Wins & Financial Dynamics

Regeneron's 2025 is marked by Dupixent's clinical breakthroughs and strategic financial shifts, impacting its market position and future growth.

Read more →
Laboratory vials and molecular structures on a sleek table with soft purple scientific background
Jun 13, 2025

Regeneron (REGN): Eylea Headwinds & Dupixent's Growth Amid Pipeline Shifts

Regeneron faces a pivotal moment in 2025, navigating Eylea's biosimilar pressures while Dupixent drives growth and new obesity deals reshape its pipeline.

Read more →
Regeneron (REGN) stock analysis highlighting Dupixent's success, diversified pharmaceutical pipeline, and financial strategy for biotech growth.
Jun 12, 2025

Regeneron's Strategic Maneuvers: Navigating Clinical Pipeline and Market Dynamics

Regeneron's stock dips slightly despite strong Dupixent data and strategic pipeline moves, highlighting complex investor sentiment.

Read more →
A visual representing Regeneron Pharmaceuticals' strategic entry into the high-growth obesity market, highlighting its portfolio diversification, R&D investments, and robust financial performance within the dynamic biotech landscape.
Jun 11, 2025

Regeneron (REGN) Analysis: Obesity Market Entry & Pipeline Shifts

Regeneron Pharmaceuticals navigates pipeline shifts and strategic expansions, entering the obesity market while managing clinical setbacks. Data-driven analysis reveals financial resilience and future growth drivers.

Read more →
Regeneron Pharmaceuticals: Analyzing Recent Financials & Strategic Moves
Jun 5, 2025

Regeneron Pharmaceuticals: Analyzing Recent Financials & Strategic Moves

Exploring Regeneron's latest financial results, strategic pipeline moves, and clinical trial outcomes, and their impact on the company's market position and future growth.

Read more →
Regeneron (REGN) stock analysis: Strategic investments in genomics and R&D, pipeline advancements, and financial performance review.
May 28, 2025

Regeneron (REGN) Analysis: Strategic Tech Adoption & Pipeline Progress

Regeneron Pharmaceuticals is making strategic moves in genomics and AI while advancing its oncology pipeline. Explore the financial implications.

Read more →
Visualizing Regeneron (REGN) biotech news: Success (Dupixent approval) and setback (EYLEA HD regulatory hurdle), illustrating the pharmaceutical market's dynamic challenges and opportunities.
Apr 21, 2025

Regeneron's Mixed Regulatory News: Dupixent Win, EYLEA HD Setback

Regeneron ([REGN](/dashboard/companies/REGN)) sees Dupixent approved for CSU, a new market, while EYLEA HD extended dosing faces FDA setback, impacting competitive positioning.

Read more →
Regeneron's strategic growth: Dupixent expansion, Eylea's resilience, and pipeline innovation drive REGN stock analysis.
Apr 9, 2025

Regeneron (REGN): Dupixent's Expansion and Eylea's Resilience

Regeneron navigates market dynamics with Dupixent's COPD approval in Japan and Eylea's resilience against biosimilars. A deep dive into financials and strategic moves.

Read more →
Regeneron's strategic navigation: Dupixent growth, Eylea competition, and R&D advancements.
Apr 2, 2025

Regeneron (REGN): Dupixent's Growth vs. Eylea's Challenges - A Financial Analysis

Regeneron (REGN) navigates Dupixent's growth against Eylea's biosimilar challenges. Strategic R&D and collaborations are key for sustained financial health.

Read more →
Regeneron Pharmaceuticals: Navigating Biosimilar Competition, Dupixent Growth, and Legal Challenges - An Investment Analysis
Mar 14, 2025

Regeneron (REGN): Eylea's Challenge, Dupixent's Promise, and R&D Power

Regeneron navigates Eylea biosimilar competition with Dupixent's growth and strategic R&D investments. Legal challenges and market dynamics shape its outlook.

Read more →
Regeneron (REGN) stock analysis: Lawsuits, Eylea concerns, and Dupixent growth impacting stock performance. Get insights on valuation, risks, and future prospects.
Mar 11, 2025

Regeneron (REGN) Stock Under Pressure: Class Action Lawsuits and Eylea Concerns

Regeneron (REGN) faces lawsuits and Eylea scrutiny, but Dupixent's growth and a strong pipeline offer potential. Investors should weigh risks and opportunities carefully.

Read more →
Regeneron's stock performance, legal challenges, and future prospects. Analysis of financial health, EYLEA competition, and pipeline innovation.
Mar 6, 2025

Regeneron Pharmaceuticals, Inc.: Strategic Financial & Market Analysis

Detailed analysis of REGN's Q4 results, legal challenges, EYLEA competition, and pipeline innovation underpinned by robust financials.

Read more →
Regeneron faces securities lawsuits amidst market challenges, impacting investors and strategic outlook. Explore analysis of legal pressures, drug competition, and future initiatives.
Mar 3, 2025

Regeneron Pharmaceuticals: Navigating Legal and Market Headwinds

Regeneron faces securities lawsuits amid market challenges and strategic initiatives. Investors assess potential impacts and the company's ability to navigate headwinds.

Read more →
Regeneron stock, legal challenges, and drug approval: Investment analysis and market performance.
Feb 28, 2025

Regeneron: EU Approval and Legal Battles Shape REGN's Future

Regeneron faces securities fraud lawsuits amid positive EU recommendation for Linvoseltamab. EYLEA and Dupixent remain key revenue drivers.

Read more →
Regeneron (REGN) stock analysis: lawsuits, FDA review, Dupixent sales, and biosimilar competition impacting investor outlook.
Feb 27, 2025

Regeneron (REGN): Lawsuits, FDA Review, and Competitive Challenges

Regeneron (REGN) faces lawsuits amid EYLEA concerns, while an FDA review offers hope. Dupixent remains strong, but competition persists. The future hinges on innovation.

Read more →
Regeneron (REGN) Stock Analysis: Legal battles, odronextamab FDA review, EYLEA competition, and investor sentiment. Stay informed with our detailed analysis.
Feb 26, 2025

Regeneron (REGN): Legal Battles, Pipeline Hopes, and Investor Outlook

Regeneron faces securities lawsuits over EYLEA sales, while the FDA reviews odronextamab for lymphoma. Competitive pressures and pipeline developments shape investor outlook.

Read more →
Regeneron (REGN) stock analysis: lawsuits, EYLEA competition, DB-OTO gene therapy hope, financial performance, and investment risk assessment.
Feb 25, 2025

Regeneron (REGN): Lawsuits, EYLEA Competition, and Gene Therapy Hope

Regeneron faces lawsuits and EYLEA competition, but gene therapy offers hope. Investors must weigh risks and opportunities.

Read more →
Regeneron (REGN) faces securities lawsuit and EYLEA competition. Analysis of legal risks, pipeline, and investor sentiment.
Feb 24, 2025

Regeneron (REGN) in Crisis: Securities Lawsuit and EYLEA Competition

Regeneron (REGN) faces a securities lawsuit and EYLEA competition. Analysis of allegations, market impact, and strategic responses are crucial for investors.

Read more →
Regeneron faces securities lawsuits: Investor Alert - Analysis of litigation risks, financial impacts, and innovation pipeline.
Feb 21, 2025

Regeneron Pharmaceuticals Faces Securities Lawsuit: Investor Deadline Looms

Regeneron (REGN) is embroiled in a securities lawsuit over alleged Eylea pricing violations, with a critical lead plaintiff deadline on March 10, 2025.

Read more →
Tangled red yarn symbolizing complex challenges in a corporate setting.
Feb 20, 2025

Regeneron Pharmaceuticals Faces Legal and Sales Pressure Amidst EYLEA Competition

Intraday update reveals mounting legal challenges, declining EYLEA sales, and heightened competitive pressures affecting REGN.

Read more →
Gavel striking sounding block, representing legal action against a pharmaceutical company.
Feb 19, 2025

Regeneron Faces Securities Lawsuit: Investor Update

Regeneron Pharmaceuticals faces multiple securities lawsuits amid legal challenges and market pressure. Detailed analysis provided.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.